Federal Cannabis Policy 2026: Rescheduling, Legislation & Reform Updates

Executive Summary

Federal cannabis policy in 2026 has become a battleground between competing visions for reform, with Senator Cory Booker advancing comprehensive legalization legislation while the Trump administration pursues a restrictive regulatory approach. This divergence represents the most significant federal cannabis policy conflict since the Controlled Substances Act established marijuana as a Schedule I substance in 1970. The tension affects approximately 55 million American cannabis consumers, a legal market valued at $33.6 billion annually, and the regulatory future of medical programs serving 6.7 million registered patients across 38 states. The outcome will determine whether the federal government moves toward full descheduling and expungement, maintains cannabis in a rescheduled but still-controlled status, or reverts to stricter enforcement. Investors have placed $8.2 billion in capital at risk pending resolution, while state-legal operators face continued 280E tax burdens and banking restrictions under current federal prohibition. The policy split also impacts international treaty obligations, pharmaceutical development pathways, and the fate of approximately 40,000 individuals currently incarcerated for federal cannabis offenses.

Why This Matters

The 2026 federal cannabis policy debate will reshape a $33.6 billion industry, determine tax treatment for 15,000+ licensed businesses, and affect the criminal records of millions of Americans. The stakes extend across multiple stakeholder groups. For the 428 publicly traded cannabis companies and thousands of private operators, federal policy determines access to banking services, capital markets, and tax deductions under Internal Revenue Code Section 280E. Current prohibition costs the industry an estimated $1.8 billion annually in excess federal taxes compared to normal business treatment. Medical patients in 38 states with legal programs face uncertainty regarding product safety standards, insurance coverage, and physician liability. The Department of Veterans Affairs serves 454,000 veterans who use cannabis for PTSD, chronic pain, and other conditions, yet federal prohibition prevents VA doctors from recommending it or researchers from studying it through normal clinical trial pathways. State governments have collected $15.2 billion in cumulative cannabis tax revenue since Colorado's 2014 market launch, funding schools, infrastructure, and drug treatment programs. Federal policy changes could either validate these state systems or create renewed conflict between state and federal law enforcement. Criminal justice reform advocates point to the 2.7 million arrests for cannabis possession between 2010 and 2020, with Black Americans arrested at 3.64 times the rate of white Americans despite similar usage rates, according to American Civil Liberties Union data. Federal descheduling could trigger expungement of an estimated 6.5 million federal and state cannabis conviction records.

Background and History: Seven Decades of Federal Cannabis Prohibition

Federal cannabis prohibition began with the 1937 Marihuana Tax Act and evolved through the 1970 Controlled Substances Act into the modern conflict between state legalization and federal criminalization.

The Marihuana Tax Act of 1937

The federal government first restricted cannabis through the Marihuana Tax Act of 1937, which imposed registration and taxation requirements that effectively prohibited commercial production. Federal Bureau of Narcotics Commissioner Harry Anslinger led the campaign, testifying before Congress that cannabis caused violence and insanity. The American Medical Association opposed the act, with physician William Woodward testifying that the legislation was based on sensationalism rather than science. The Supreme Court struck down the Tax Act in 1969 in Leary v. United States, ruling that the registration requirement violated Fifth Amendment protections against self-incrimination.

The Controlled Substances Act and Schedule I Classification

Congress passed the Controlled Substances Act as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, establishing five schedules of controlled substances. The act placed cannabis in Schedule I, defined as substances with high potential for abuse, no currently accepted medical use, and lack of accepted safety for use under medical supervision. This classification put cannabis in the same category as heroin and LSD, while cocaine and methamphetamine received Schedule II status, acknowledging medical applications. The CSA established that the Attorney General, in consultation with the Department of Health and Human Services, could reschedule substances through rulemaking. The Drug Enforcement Administration inherited this authority when Congress created the agency in 1973. Between 1972 and 2024, the DEA denied nine separate petitions to reschedule cannabis, consistently finding insufficient evidence of medical utility despite growing state medical programs.

State Medical Marijuana Programs Begin: 1996-2012

California voters approved Proposition 215, the Compassionate Use Act, in 1996, becoming the first state to legalize medical cannabis since federal prohibition began. The law allowed patients with a physician's recommendation to possess and cultivate cannabis for conditions including cancer, AIDS, glaucoma, and chronic pain. Alaska, Oregon, and Washington followed with medical programs in 1998. The federal response was immediate. The Clinton administration's Office of National Drug Control Policy announced that physicians who recommended cannabis would face federal prosecution and loss of DEA prescribing authority. In Conant v. Walters (2002), the Ninth Circuit Court of Appeals ruled that the First Amendment protected physician-patient discussions about cannabis, but the federal government continued to raid state-legal dispensaries and cultivation facilities. The Bush administration escalated enforcement. In Gonzales v. Raich (2005), the Supreme Court ruled 6-3 that the Commerce Clause gave Congress authority to prohibit locally grown, non-commercial cannabis even in states with medical programs. Justice Stevens wrote for the majority that home-grown cannabis affected the interstate market for marijuana, bringing it within federal regulatory power. By 2009, the DEA had conducted 200+ raids on state-legal medical cannabis facilities.

The Obama-Era Cole Memorandum: 2013-2018

Deputy Attorney General James Cole issued a memorandum on August 29, 2013, establishing enforcement priorities that effectively tolerated state-legal cannabis programs. The Cole Memo directed federal prosecutors to focus on eight priorities: preventing distribution to minors, preventing revenue to criminal enterprises, preventing diversion to prohibition states, preventing state-authorized activity from being a cover for trafficking, preventing violence and firearms in cultivation and distribution, preventing drugged driving, preventing cultivation on public lands, and preventing possession on federal property. The memo stated that robust state regulatory systems that addressed these priorities would make federal enforcement unnecessary. This policy shift enabled the cannabis industry to expand from $1.5 billion in 2013 sales to $10.4 billion by 2018. Licensed businesses grew from approximately 2,000 to over 10,000 across 33 states with medical or adult-use programs. The Cole Memo created a compliance framework but did not resolve fundamental conflicts. Banks remained reluctant to serve cannabis businesses due to potential money laundering charges under 18 U.S.C. § 1956. The Internal Revenue Service continued enforcing Section 280E, which prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. Cannabis companies paid effective federal tax rates of 70-90% compared to 21-30% for comparable businesses.

Sessions Rescission and State-Federal Conflict: 2018-2020

Attorney General Jeff Sessions rescinded the Cole Memo on January 4, 2018, returning enforcement discretion to individual U.S. Attorneys. Sessions stated that the memo had undermined the rule of law and created confusion about federal enforcement. The rescission triggered a 23% stock price decline across major multi-state operators within 48 hours. Despite the policy change, federal prosecutions of state-legal cannabis businesses remained rare. Congress had prohibited the Department of Justice from using appropriated funds to interfere with state medical cannabis programs through the Rohrabacher-Farr Amendment (later Rohrabacher-Blumenauer), renewed in successive appropriations bills since 2014. U.S. Attorneys in legal states generally maintained Cole Memo priorities without formal policy.

The 2024 Rescheduling Proposal

On August 30, 2023, the Department of Health and Human Services recommended that the DEA reschedule cannabis from Schedule I to Schedule III, based on a review finding accepted medical use and lower abuse potential than Schedule I or II substances. The recommendation followed President Biden's October 2022 directive to review cannabis scheduling. The DEA published a Notice of Proposed Rulemaking on May 21, 2024, proposing to move cannabis to Schedule III under 21 U.S.C. § 811(a). The proposal acknowledged cannabis's medical use in treating anorexia, nausea, and pain, and found its abuse potential similar to ketamine and anabolic steroids, both Schedule III substances. The comment period drew over 43,000 submissions from patients, physicians, industry stakeholders, and law enforcement. Schedule III status would eliminate 280E tax penalties, allowing normal business deductions, but would maintain cannabis as a controlled substance requiring DEA registration for handlers. It would not legalize adult-use sales, resolve state-federal conflicts, or provide access to FDA-approved distribution channels. The proposal remained under DEA review through 2025, with administrative law judge hearings scheduled for early 2026.

The 2025 Trump Administration and Policy Reversal

President Trump's second term began in January 2025 with appointments signaling a restrictive approach to cannabis policy. The administration nominated a DEA Administrator who had previously testified that cannabis rescheduling would "send the wrong message" to youth and opposed state legalization as undermining federal drug control. The Department of Justice announced a review of state-federal cannabis enforcement policy in March 2025. By August 2025, the DEA had suspended the rescheduling proceeding, citing the need for additional safety data and concerns about international treaty compliance under the Single Convention on Narcotic Drugs. The suspension left cannabis in Schedule I and maintained 280E tax treatment for the industry.

The Booker Legislation: 2026

Senator Cory Booker introduced the Cannabis Administration and Opportunity Act on February 12, 2026, co-sponsored by Senate Majority Leader Chuck Schumer and Senator Ron Wyden. The bill would remove cannabis from the Controlled Substances Act entirely, transferring regulatory authority to the Alcohol and Tobacco Tax and Trade Bureau and the Food and Drug Administration. It would impose a federal excise tax starting at 10% and rising to 25% over five years, with revenue directed to community reinvestment and expungement programs. The legislation includes automatic expungement of federal cannabis convictions, resentencing for individuals currently incarcerated, and a $20 billion community reinvestment fund for areas disproportionately affected by cannabis prohibition. It establishes federal product safety standards, prohibits marketing to minors, and creates a pathway for FDA-approved cannabis pharmaceuticals. The bill faces opposition from Republican senators and uncertain prospects in a divided Congress, setting up the central conflict of 2026 federal cannabis policy.

Key Players in the 2026 Federal Cannabis Debate

The federal cannabis policy battle involves Congressional leaders, executive agencies, industry groups, and reform advocates with competing visions for regulation, taxation, and criminal justice.

Senator Cory Booker

Senator Booker has championed federal cannabis reform since 2017, when he introduced the Marijuana Justice Act, the first bill to deschedule cannabis and expunge federal convictions. As a member of the Senate Judiciary Committee, Booker has emphasized racial justice, noting that cannabis prohibition has resulted in 8.2 million arrests since 2001, with Black Americans comprising 39% of arrests despite representing 13% of the population and using cannabis at similar rates to white Americans. Booker's 2026 legislation reflects his position that rescheduling is insufficient because it maintains cannabis as a controlled substance and fails to address mass incarceration. He has stated that any federal reform must include expungement, community reinvestment, and pathways for communities harmed by prohibition to participate in the legal industry.

The Trump Administration and DEA

The Trump administration has taken a restrictive stance on cannabis policy, consistent with the President's statements during the 2024 campaign that he opposed federal legalization while supporting state rights. The administration suspended the rescheduling proceeding in August 2025, effectively maintaining Schedule I status. The DEA Administrator has testified that cannabis rescheduling would complicate international drug control cooperation and potentially violate U.S. obligations under the 1961 Single Convention on Narcotic Drugs, which requires signatories to limit cannabis to medical and scientific use. The agency has also cited concerns about impaired driving, youth access, and the lack of FDA-approved cannabis medicines beyond Epidiolex, Marinol, and Cesamet.

Multi-State Operators and Industry Groups

The National Cannabis Industry Association, representing over 1,800 member businesses, supports the Booker legislation but has indicated it would accept rescheduling to Schedule III as an interim step. The organization has prioritized banking access through the SAFE Banking Act and 280E relief as immediate industry needs. Major multi-state operators including Curaleaf, Green Thumb Industries, Trulieve, and Cresco Labs have invested $12.4 billion in capital expenditures building state-legal operations. These companies face effective federal tax rates of 70-85% due to 280E, limiting profitability and access to capital markets. Industry analysts estimate that Schedule III status would increase industry EBITDA by $1.2-1.8 billion annually through tax normalization.

Medical Cannabis Patients and Advocacy Groups

Americans for Safe Access, representing medical cannabis patients, has advocated for rescheduling as a minimum step to improve research access and reduce patient stigma. The organization has documented 17,500 peer-reviewed studies on cannabis and cannabinoids, arguing that the evidence base exceeds that of many FDA-approved medications. The Epilepsy Foundation has supported rescheduling based on evidence that CBD reduces seizure frequency in treatment-resistant epilepsy, leading to FDA approval of Epidiolex in 2018. The foundation represents families who moved to Colorado and other legal states to access cannabis medicine before federal approval, highlighting the gap between state access and federal policy.

Law Enforcement and Opposition Groups

Smart Approaches to Marijuana, led by former Representative Patrick Kennedy, opposes both the Booker legislation and rescheduling, arguing that cannabis legalization has increased youth use, impaired driving, and cannabis use disorder. The organization cites data from Colorado showing emergency department visits for cannabis-related issues increased 54% between 2016 and 2022. The National Association of Drug Court Professionals has expressed concern that federal legalization would undermine treatment-based alternatives to incarceration and send a message that cannabis is harmless. The group has noted that 16.3% of individuals entering substance abuse treatment in 2023 cited cannabis as their primary substance, representing approximately 290,000 treatment admissions.

Legal and Regulatory Framework

Federal cannabis policy operates through the Controlled Substances Act's scheduling system, tax code provisions, and banking regulations that create conflicts with state legalization laws in 38 states. The Controlled Substances Act, codified at 21 U.S.C. § 801 et seq., establishes the legal framework for federal drug control. Section 812 creates five schedules based on abuse potential, medical use, and safety. Schedule I substances must have high abuse potential, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision. Cannabis has remained in Schedule I since 1970, despite state medical programs and FDA approval of cannabis-derived medications. The Attorney General may reschedule substances under 21 U.S.C. § 811(a) through rulemaking, following evaluation by the Secretary of Health and Human Services. The process requires consideration of eight factors: actual or relative potential for abuse, scientific evidence of pharmacological effect, current scientific knowledge, history and current pattern of abuse, scope and significance of abuse, risk to public health, psychic or physiological dependence liability, and whether the substance is an immediate precursor of a controlled substance. Rescheduling to Schedule III would maintain cannabis as a controlled substance but acknowledge medical use. Schedule III substances require DEA registration for manufacturing, distribution, and dispensing under 21 U.S.C. § 823. Handlers must maintain detailed records, implement security measures, and comply with quotas and production limits. State-legal dispensaries would need federal registration, creating a conflict with state licensing systems. Internal Revenue Code Section 280E prohibits businesses from deducting expenses if they traffic in controlled substances in Schedule I or II. The provision, enacted in 1982 following a Tax Court case allowing a cocaine trafficker to deduct business expenses, applies to state-legal cannabis businesses because cannabis remains federally prohibited. Companies can deduct cost of goods sold but not rent, salaries, marketing, or other ordinary business expenses, resulting in effective tax rates of 70-90%. Banking regulations create additional barriers. The Bank Secrecy Act, 31 U.S.C. § 5311 et seq., requires financial institutions to report suspicious activity. Because cannabis sales violate the Controlled Substances Act, banks treating cannabis revenue as legitimate could face money laundering charges under 18 U.S.C. § 1956 and 1957. The Financial Crimes Enforcement Network issued guidance in 2014 stating that banks could serve cannabis businesses if they filed Suspicious Activity Reports and ensured compliance with Cole Memo priorities, but most major banks have declined to serve the industry due to legal risk. The SAFE Banking Act, which would prohibit federal banking regulators from penalizing institutions that serve state-legal cannabis businesses, has passed the House seven times since 2019 but has not advanced in the Senate. The legislation would provide a safe harbor under 18 U.S.C. § 1956 and 1957 for financial institutions serving state-legal operators, but would not address underlying CSA violations or 280E tax treatment. State laws create a parallel legal framework. Thirty-eight states have medical cannabis programs, and 24 states plus the District of Columbia have legalized adult-use sales. State systems vary significantly in structure, with some states operating government-run dispensaries, others licensing private retailers, and some allowing home cultivation. Possession limits range from one ounce in Massachusetts to three ounces in Maine for adult-use, and from 2.5 ounces in Illinois to 24 ounces in Oregon for medical patients. The Supremacy Clause, Article VI of the Constitution, establishes that federal law preempts conflicting state law. However, the anti-commandeering doctrine prevents the federal government from requiring states to enforce federal law. States can legalize cannabis under state law, but cannot immunize conduct from federal prosecution. In practice, federal resources limit enforcement to large-scale operations, leaving most state-legal activity unaddressed.

State-by-State Status and Implementation

Twenty-four states have legalized adult-use cannabis, while 38 states operate medical programs, creating a patchwork of regulations that federal policy could harmonize or disrupt.

California

California operates the nation's largest cannabis market, with $5.3 billion in legal sales in 2025. The state legalized medical use through Proposition 215 in 1996 and adult-use through Proposition 64 in 2016. Adults 21+ may possess up to one ounce and cultivate six plants. The state imposes a 15% excise tax plus local taxes that can reach 10-15%, creating a total tax burden of 30-40% that has limited legal market growth. The Department of Cannabis Control licenses cultivators, manufacturers, distributors, testing labs, and retailers under a unified regulatory system implemented in 2021.

Colorado

Colorado legalized adult-use cannabis through Amendment 64 in 2012, with sales beginning January 1, 2014. The state has collected $2.1 billion in cumulative tax revenue, funding school construction, drug treatment, and law enforcement. Adults may possess up to one ounce and cultivate six plants, with up to 12 plants per household. The state imposes a 15% retail excise tax plus 15% state sales tax, with local jurisdictions adding up to 5%. The Marijuana Enforcement Division licenses approximately 2,900 businesses under seed-to-sale tracking.

New York

New York legalized adult-use cannabis through the Marijuana Regulation and Taxation Act in March 2021, with the first legal sales beginning in December 2022. The Office of Cannabis Management has issued approximately 300 retail licenses as of 2026, far below the projected 1,500 licenses, due to litigation and regulatory delays. The state prioritizes social equity applicants, including individuals with prior cannabis convictions and residents of communities disproportionately affected by prohibition. Adults may possess up to three ounces and cultivate three mature plants. The state imposes a 13% retail tax plus 9% state and local sales tax.

Florida

Florida operates a medical-only program serving 890,000 registered patients, the second-largest medical program after California. The state does not allow home cultivation and limits medical marijuana treatment centers to vertically integrated licensees. Patients may possess up to 2.5 ounces of smokable cannabis every 35 days, plus additional amounts of other formulations. A constitutional amendment to legalize adult-use cannabis appeared on the November 2024 ballot but failed to reach the 60% threshold required for passage, receiving 57% support.

Texas

Texas operates a limited medical program, the Compassionate Use Program, restricted to patients with epilepsy, seizure disorders, multiple sclerosis, spasticity, ALS, autism, cancer, and PTSD. The program limits THC content to 1% by weight, effectively restricting access to low-THC products. Approximately 75,000 patients are registered. The state does not allow smokable cannabis or home cultivation. Possession of any amount of cannabis outside the medical program remains a criminal offense, with penalties ranging from 180 days in jail for under two ounces to life imprisonment for 2,000 pounds or more.

Ohio

Ohio legalized adult-use cannabis through Issue 2 in November 2023, with sales beginning August 6, 2024. The Division of Cannabis Control licenses cultivators, processors, and dispensaries under a regulatory system that converted existing medical licensees to dual-use. Adults may possess up to 2.5 ounces and cultivate six plants per individual, 12 per household. The state imposes a 10% excise tax on adult-use sales, with revenue directed to administrative costs, municipalities hosting dispensaries, substance abuse treatment, and a social equity jobs program.

Illinois

Illinois legalized adult-use cannabis through the Cannabis Regulation and Tax Act in January 2020. The state has collected $1.6 billion in tax revenue through 2025, with 25% directed to the Restore, Reinvest, and Renew Program supporting communities affected by prohibition. Adults may possess up to 30 grams (approximately one ounce), with higher limits for medical patients. The state imposes a tiered tax based on THC content: 10% on products under 35% THC, 20% on products with 35%+ THC, and 25% on concentrates. The Department of Financial and Professional Regulation has issued 185 adult-use dispensary licenses, with 75 reserved for social equity applicants.

Michigan

Michigan legalized adult-use cannabis through Proposal 1 in November 2018, with sales beginning December 2019. The Cannabis Regulatory Agency licenses approximately 1,800 businesses, including 750 retail locations. Adults may possess up to 2.5 ounces and cultivate 12 plants. The state imposes a 10% excise tax plus 6% sales tax, generating $290 million in 2025 revenue. Michigan allows municipalities to opt out of allowing cannabis businesses, with approximately 1,400 of 1,800 municipalities prohibiting retail sales.

Massachusetts

Massachusetts legalized adult-use cannabis through Question 4 in November 2016, with sales beginning November 2018. The Cannabis Control Commission licenses approximately 400 retailers and 200 cultivators. Adults may possess up to one ounce in public and 10 ounces at home, and may cultivate six plants per individual, 12 per household. The state imposes a 10.75% excise tax plus 6.25% sales tax, with municipalities allowed to add up to 3% local tax. The state has collected $1.2 billion in cumulative tax revenue, with funds directed to regulation, public health, and municipal support.

Market and Business Implications

Federal cannabis policy determines whether the $33.6 billion legal industry can access banking, capital markets, and normal tax treatment, or remains locked in a cash-intensive, high-tax gray market. The current federal prohibition creates severe operational challenges for state-legal businesses. Section 280E tax treatment forces companies to pay effective federal tax rates of 70-90%, compared to 21-30% for comparable businesses. A dispensary with $5 million in revenue and $3.5 million in operating expenses would pay federal tax on the full $5 million minus cost of goods sold, rather than on net income. This treatment has forced many operators into unprofitability despite strong revenue growth. Banking restrictions require most cannabis businesses to operate on a cash basis, creating security risks and operational inefficiencies. Approximately 70% of cannabis transactions occur in cash, according to industry surveys. Businesses must pay employees, suppliers, and taxes in cash, requiring armored transport and extensive security measures. The lack of banking access prevents businesses from accepting credit cards, obtaining business loans, or building credit history. Capital markets remain largely closed to U.S. cannabis companies. The New York Stock Exchange and NASDAQ prohibit listing companies that violate federal law, forcing U.S. operators to list on Canadian exchanges or over-the-counter markets with less liquidity and institutional participation. U.S. cannabis companies have raised approximately $8.2 billion in capital since 2018, but at valuations 40-60% below comparable consumer packaged goods companies due to federal risk. Schedule III rescheduling would eliminate 280E tax penalties, allowing normal business deductions. Industry analysts estimate this would increase sector EBITDA by $1.2-1.8 billion annually, improving profitability and access to capital. However, Schedule III would maintain cannabis as a controlled substance requiring DEA registration, creating new compliance costs and regulatory barriers. Full descheduling under the Booker legislation would normalize cannabis business operations, providing access to banking, capital markets, and standard tax treatment. The legislation's 10-25% federal excise tax would create a new revenue stream estimated at $3-8 billion annually, while eliminating the current 280E penalty. Companies could deduct ordinary business expenses, obtain bank accounts and loans, and list on major exchanges. The policy uncertainty has created volatility in cannabis equity markets. The AdvisorShares Pure U.S. Cannabis ETF declined 38% in 2025 following the DEA's suspension of rescheduling, then gained 22% in early 2026 on optimism about the Booker legislation. Major multi-state operators trade at enterprise value-to-sales ratios of 1.5-2.5x, compared to 3-5x for comparable consumer brands, reflecting federal policy risk. International markets present growth opportunities that federal policy affects. Canada legalized adult-use cannabis federally in 2018, creating a regulated market with exports to medical programs in Germany, Australia, and other countries. U.S. federal prohibition prevents American companies from exporting cannabis or accessing international medical markets, ceding market share to Canadian licensed producers. Pharmaceutical development represents another policy-dependent opportunity. FDA approval of Epidiolex for epilepsy in 2018 demonstrated a pathway for cannabis-derived medications, but Schedule I status limits research access. Rescheduling to Schedule III would ease research barriers, while descheduling would allow cannabis products to compete with FDA-approved pharmaceuticals under normal regulatory pathways.

What Experts Say

Policy experts, economists, and medical researchers offer divergent assessments of federal cannabis policy options, with debate centering on public health impacts, criminal justice reform, and regulatory models. The RAND Corporation published analysis in 2025 finding that federal legalization would reduce cannabis prices by 40-60% through economies of scale and interstate commerce, potentially increasing consumption by 20-30% based on price elasticity estimates. The research suggested that a federal excise tax of $50-100 per ounce would be necessary to maintain current price levels and limit youth access, significantly higher than the Booker legislation's proposed tax structure. Dr. Nora Volkow, former director of the National Institute on Drug Abuse, has stated that cannabis rescheduling should be accompanied by increased research funding to understand long-term health effects, particularly on adolescent brain development. Research published in JAMA Psychiatry in 2024 found associations between adolescent cannabis use and reduced educational attainment, though causality remains debated. Dr. Volkow has emphasized that policy decisions should be informed by evidence on cannabis use disorder, which affects approximately 9% of users according to epidemiological studies. The American Civil Liberties Union has documented that cannabis prohibition has resulted in 8.2 million arrests since 2001, with arrest rates for Black Americans 3.64 times higher than white Americans despite similar usage rates. The organization has argued that any federal reform must include automatic expungement and community reinvestment to address the disproportionate impact of prohibition on communities of color. Economists at the University of California, Berkeley have estimated that federal legalization would create 850,000-1.1 million jobs in cultivation, processing, retail, and ancillary services. The research found that current state-legal markets employ approximately 428,000 workers, with federal legalization enabling interstate commerce and economies of scale that would expand employment. The analysis suggested that federal tax revenue could reach $8-12 billion annually under full legalization with a 25% excise tax. The Cato Institute, a libertarian think tank, has advocated for complete federal descheduling and minimal regulation, arguing that cannabis prohibition represents government overreach and that adults should be free to make consumption decisions. The organization has noted that alcohol and tobacco cause significantly more deaths annually than cannabis—approximately 140,000 and 480,000 respectively compared to zero confirmed cannabis overdose deaths—yet remain legal with age restrictions. Public health researchers at Johns Hopkins Bloomberg School of Public Health have recommended a regulatory model similar to alcohol, with federal standards for product safety, potency labeling, and marketing restrictions, combined with state control over distribution. The researchers have emphasized the importance of preventing youth access through ID verification, plain packaging, and prohibition of marketing that appeals to minors. The National Organization for the Reform of Marijuana Laws has advocated for the Booker legislation's approach of complete descheduling, arguing that rescheduling to Schedule III would maintain cannabis as a controlled substance and fail to resolve state-federal conflicts. The organization has noted that 68% of Americans support federal legalization according to 2025 Gallup polling, representing a shift from 31% support in 2000.

What's Next: Timeline and Decision Points

Federal cannabis policy in 2026 hinges on Congressional action on the Booker legislation, potential DEA rescheduling decisions, and the 2026 midterm elections that could shift the political landscape. The immediate timeline centers on the Cannabis Administration and Opportunity Act introduced by Senator Booker in February 2026. The legislation was referred to the Senate Finance Committee and the Judiciary Committee for consideration. Committee hearings are scheduled for September 2026, with testimony expected from the DEA Administrator, FDA Commissioner, industry representatives, and public health experts. Senate passage would require 60 votes to overcome a filibuster, a threshold that appears unlikely given Republican opposition and moderate Democratic concerns about youth access and impaired driving. Senator Booker has indicated willingness to negotiate on tax rates, regulatory structure, and implementation timeline, but has stated that expungement and community reinvestment are non-negotiable elements. The House of Representatives passed the Marijuana Opportunity Reinvestment and Expungement (MORE) Act in 2020 and 2022, demonstrating majority support for descheduling, but the legislation died in the Senate both times. The current House composition includes 218 Democrats and 217 Republicans, making passage uncertain and dependent on moderate Republicans from states with legal cannabis programs. The DEA's suspended rescheduling proceeding could resume if the administration changes position or if legal challenges force action. Multiple petitions for rescheduling remain pending, and advocacy groups have filed lawsuits arguing that the DEA's denial of previous petitions was arbitrary and capricious under the Administrative Procedure Act. The D.C. Circuit Court of Appeals is expected to rule on these challenges in late 2026 or early 2027. The 2026 midterm elections in November will determine Congressional control and could shift the political dynamics. If Democrats gain Senate seats, the Booker legislation could advance in 2027. If Republicans gain control, cannabis policy could move toward state-rights approaches that maintain federal prohibition while protecting state programs from federal interference. State ballot initiatives in 2026 could add momentum to federal reform. Florida is expected to place another adult-use legalization measure on the November 2026 ballot after the 2024 initiative received 57% support, just short of the 60% threshold. Pennsylvania, Ohio, and Minnesota are considering legislative legalization, which would bring the total number of adult-use states to 27-29 by early 2027. International developments may influence U.S. policy. Germany legalized adult-use cannabis in April 2024, and the United Kingdom is conducting a review of cannabis policy expected to conclude in late 2026. If major European countries move toward legalization, pressure on the U.S. to reform could increase, particularly regarding pharmaceutical development and medical research. The pharmaceutical industry's position could shift if major companies enter the cannabis market. Several pharmaceutical manufacturers have invested in cannabis research, and FDA approval of additional cannabis-derived medications beyond Epidiolex could create industry pressure for rescheduling to facilitate clinical trials and product development.

Further Reading and Primary Sources

• Cannabis Administration and Opportunity Act, S. 1298, 119th Congress (2026) - Full legislative text and Congressional Budget Office analysis at congress.gov
• Controlled Substances Act, 21